We also showed that cancer-associated mutations in SPOP led to decreased levels of LMNB2 and compromised NE integrity, making SPOP-mutant cells more susceptible to NE rupture and vulnerable to farnesyltransferase inhibition. The gene discussed is SPOP; the disease is cancer.